Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jun 15;101(12):2869–2874. doi: 10.1172/JCI1524

Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma.

A G Rossi 1, C Haslett 1, N Hirani 1, A P Greening 1, I Rahman 1, C N Metz 1, R Bucala 1, S C Donnelly 1
PMCID: PMC508878  PMID: 9637721

Abstract

Macrophage migration inhibitory factor (MIF) is a potent proinflammatory mediator that has been shown to potentiate lethal endotoxemia and to play a potentially important regulatory role in human acute respiratory distress syndrome (ARDS). We have investigated whether eosinophils are an important source of MIF and whether MIF may be involved in the pathophysiology of asthma. Unstimulated human circulating eosinophils were found to contain preformed MIF. Stimulation of human eosinophils with phorbol myristate acetate in vitro yielded significant release of MIF protein. For example, eosinophils stimulated with phorbol myristate acetate (100 nM, 8 h, 37 degreesC) released 1,539+/-435 pg/10(6) cells of MIF, whereas unstimulated cells released barely detectable levels (< 142 pg/10(6) cells, mean+/-SEM, n = 8). This stimulated release was shown to be (a) concentration- and time-dependent, (b) partially blocked by the protein synthesis inhibitor cycloheximide, and (c) significantly inhibited by the protein kinase C inhibitor Ro-31,8220. In addition, we show that the physiological stimuli C5a and IL-5 also cause significant MIF release. Furthermore, bronchoalveolar lavage fluid obtained from asthmatic patients contains significantly elevated levels of MIF as compared to nonatopic normal volunteers (asthmatic, 797.5+/-92 pg/ml; controls, 274+/-91 pg/ml). These results highlight the potential importance of MIF in asthma and other eosinophil-dependent inflammatory disorders.

Full Text

The Full Text of this article is available as a PDF (151.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacher M., Metz C. N., Calandra T., Mayer K., Chesney J., Lohoff M., Gemsa D., Donnelly T., Bucala R. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7849–7854. doi: 10.1073/pnas.93.15.7849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barnes P. J., Adcock I. M. Steroid resistance in asthma. QJM. 1995 Jul;88(7):455–468. [PubMed] [Google Scholar]
  3. Barnes P. J., Greening A. P., Crompton G. K. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 2):S125–S140. doi: 10.1164/ajrccm/152.6_Pt_2.S125. [DOI] [PubMed] [Google Scholar]
  4. Bernhagen J., Bacher M., Calandra T., Metz C. N., Doty S. B., Donnelly T., Bucala R. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med. 1996 Jan 1;183(1):277–282. doi: 10.1084/jem.183.1.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bernhagen J., Calandra T., Mitchell R. A., Martin S. B., Tracey K. J., Voelter W., Manogue K. R., Cerami A., Bucala R. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993 Oct 21;365(6448):756–759. doi: 10.1038/365756a0. [DOI] [PubMed] [Google Scholar]
  6. Bernhagen J., Mitchell R. A., Calandra T., Voelter W., Cerami A., Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry. 1994 Nov 29;33(47):14144–14155. doi: 10.1021/bi00251a025. [DOI] [PubMed] [Google Scholar]
  7. Bloom B. R., Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966 Jul 1;153(3731):80–82. doi: 10.1126/science.153.3731.80. [DOI] [PubMed] [Google Scholar]
  8. Calandra T., Bernhagen J., Metz C. N., Spiegel L. A., Bacher M., Donnelly T., Cerami A., Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995 Sep 7;377(6544):68–71. doi: 10.1038/377068a0. [DOI] [PubMed] [Google Scholar]
  9. Calandra T., Bernhagen J., Mitchell R. A., Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994 Jun 1;179(6):1895–1902. doi: 10.1084/jem.179.6.1895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. David J. R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A. 1966 Jul;56(1):72–77. doi: 10.1073/pnas.56.1.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Donnelly S. C., Bucala R. Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today. 1997 Nov;3(11):502–507. doi: 10.1016/S1357-4310(97)01133-7. [DOI] [PubMed] [Google Scholar]
  12. Donnelly S. C., Haslett C., Reid P. T., Grant I. S., Wallace W. A., Metz C. N., Bruce L. J., Bucala R. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med. 1997 Mar;3(3):320–323. doi: 10.1038/nm0397-320. [DOI] [PubMed] [Google Scholar]
  13. GEORGE M., VAUGHAN J. H. In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exp Biol Med. 1962 Nov;111:514–521. doi: 10.3181/00379727-111-27841. [DOI] [PubMed] [Google Scholar]
  14. Greening A. P., Nunn P., Dobson N., Rudolf M., Rees A. D. Pulmonary sarcoidosis: alterations in bronchoalveolar lymphocytes and T cell subsets. Thorax. 1985 Apr;40(4):278–283. doi: 10.1136/thx.40.4.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kay A. B., Barata L., Meng Q., Durham S. R., Ying S. Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):196–199. doi: 10.1159/000237545. [DOI] [PubMed] [Google Scholar]
  16. Lan H. Y., Bacher M., Yang N., Mu W., Nikolic-Paterson D. J., Metz C., Meinhardt A., Bucala R., Atkins R. C. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med. 1997 Apr 21;185(8):1455–1465. doi: 10.1084/jem.185.8.1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lan H. Y., Mu W., Yang N., Meinhardt A., Nikolic-Paterson D. J., Ng Y. Y., Bacher M., Atkins R. C., Bucala R. De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol. 1996 Oct;149(4):1119–1127. [PMC free article] [PubMed] [Google Scholar]
  18. Lee J. J., McGarry M. P., Farmer S. C., Denzler K. L., Larson K. A., Carrigan P. E., Brenneise I. E., Horton M. A., Haczku A., Gelfand E. W. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med. 1997 Jun 16;185(12):2143–2156. doi: 10.1084/jem.185.12.2143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Martin L. B., Kita H., Leiferman K. M., Gleich G. J. Eosinophils in allergy: role in disease, degranulation, and cytokines. Int Arch Allergy Immunol. 1996 Mar;109(3):207–215. doi: 10.1159/000237239. [DOI] [PubMed] [Google Scholar]
  20. Meagher L. C., Cousin J. M., Seckl J. R., Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996 Jun 1;156(11):4422–4428. [PubMed] [Google Scholar]
  21. Nishino T., Bernhagen J., Shiiki H., Calandra T., Dohi K., Bucala R. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med. 1995 Nov;1(7):781–788. [PMC free article] [PubMed] [Google Scholar]
  22. Schleimer R. P. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol. 1993;45 (Suppl 1):S3–S44. doi: 10.1007/BF01844196. [DOI] [PubMed] [Google Scholar]
  23. Schleimer R. P., Bochner B. S. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1202–1213. doi: 10.1016/0091-6749(94)90333-6. [DOI] [PubMed] [Google Scholar]
  24. Stern M., Meagher L., Savill J., Haslett C. Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol. 1992 Jun 1;148(11):3543–3549. [PubMed] [Google Scholar]
  25. Teixeira M. M., Williams T. J., Hellewell P. G. Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo. Trends Pharmacol Sci. 1995 Dec;16(12):418–423. doi: 10.1016/s0165-6147(00)89092-6. [DOI] [PubMed] [Google Scholar]
  26. Teran L. M., Campos M. G., Begishvilli B. T., Schröder J. M., Djukanovic R., Shute J. K., Church M. K., Holgate S. T., Davies D. E. Identification of neutrophil chemotactic factors in bronchoalveolar lavage fluid of asthmatic patients. Clin Exp Allergy. 1997 Apr;27(4):396–405. [PubMed] [Google Scholar]
  27. Thomas L. H., Warner J. A. The eosinophil and its role in asthma. Gen Pharmacol. 1996 Jun;27(4):593–597. doi: 10.1016/0306-3623(95)02045-4. [DOI] [PubMed] [Google Scholar]
  28. Woolley K. L., Gibson P. G., Carty K., Wilson A. J., Twaddell S. H., Woolley M. J. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med. 1996 Jul;154(1):237–243. doi: 10.1164/ajrccm.154.1.8680686. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES